Latest / Markets & Money News Today | 2 Min News | THE DAILY NOW!
Johnson & Johnson's Cancer Drug Shows Promise | Markets & Money News
Johnson & Johnson's experimental prostate cancer drug, JNJ-6143, has shown promising results in an early trial involving patients with advanced disease. Out of 31 participants who took a daily dose, 77% experienced a significant reduction in prostate-specific antigen levels, while 69% had confirmed complete or partial responses in measurable tumors. The drug, acquired through J&J's $3.05 billion purchase of Halda Therapeutics, utilizes a new mechanism to target cancer cells. Although promising,
www.TheDailyNewsNow.com
This is an automated, high-level news summary based on public reporting and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.